Sign In
Buy ELV
$416.23
-4.16 (-0.99%)
At Close: Jul 10, 2026
Elevance Health: Defense For An Undervalued Price
08:45am, Saturday, 11'th Jul 2026
Elevance Health has outperformed the benchmark, rising 28% versus 11%, and I see further upside potential. ELV demonstrates steady top- and bottom-line growth, supporting a premium multiple and reinfo
Is ELV's Capital Allocation Strategy Creating Long-Term Value?
01:25pm, Friday, 10'th Jul 2026
Elevance Health's disciplined capital allocation, strong cash generation and continued investments in Carelon and AI support long-term growth while rewarding shareholders.
Curious about Elevance Health (ELV) Q2 Performance? Explore Wall Street Estimates for Key Metrics
10:16am, Friday, 10'th Jul 2026
Beyond analysts' top-and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the q
3 Cheap Medical Stocks to Buy as US-Iran Tensions Keep Markets on Edge
03:26pm, Thursday, 09'th Jul 2026
U.S.-Iran tensions likely to lift demand for defensive plays, with Tenet Healthcare, Elevance Health and Aveanna Healthcare standing out as cheap medical stocks.
Analysts Estimate Elevance Health (ELV) to Report a Decline in Earnings: What to Look Out for
11:01am, Wednesday, 08'th Jul 2026
Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
04:30pm, Monday, 06'th Jul 2026
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review t
Can Elevance Recover $115 Million Through Its CMS Lawsuit?
11:15am, Friday, 03'rd Jul 2026
ELV seeks to recover an estimated $115 million through a CMS lawsuit over Medicare Advantage Star Ratings and disputed bonus payments.
Can Carelon Drive Elevance Health's Future Earnings Growth?
12:46pm, Friday, 26'th Jun 2026
Carelon is becoming a major growth driver for ELV, boosting revenues, care efficiency and long-term earnings potential despite near-term investment pressure.
New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
09:00am, Thursday, 25'th Jun 2026
INDIANAPOLIS--(BUSINESS WIRE)--The No Surprises Act was created to protect patients from unexpected medical bills. While those patient protections are working, new research from the Elevance Health Pu
INDIANAPOLIS--(BUSINESS WIRE)--Thomas Carr Howe Middle School today celebrated the unveiling of a newly transformed fitness and strength training space made possible through a partnership with Elevanc
ELV Accelerates Clinical Reviews Through Health OS Platform
12:42pm, Wednesday, 24'th Jun 2026
Elevance Health's Health OS is cutting review delays and admin work, with early results showing fewer denials and holds as digital healthcare adoption expands.
Elevance Health (ELV) Upgraded to Buy: Here's What You Should Know
01:01pm, Tuesday, 23'rd Jun 2026
Elevance Health (ELV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Elevance Health Makes Clinical Review Faster, More Connected with Health OS
08:15am, Tuesday, 23'rd Jun 2026
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health today announced advancements in how it helps streamline clinical review and create a simpler, faster, and more connected experience for care providers an
Elevance Tops $1B in Housing Investments: What's Driving the Strategy?
01:46pm, Thursday, 18'th Jun 2026
ELV surpasses $1B in affordable housing investments, aiming to improve health outcomes, expand care access and support long-term growth.
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
